Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entitiesLecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research
Michael Mark illustrates the full trajectory of development of the SGLT2 inhibitor empagliflozin, from finding a therapeutic target through testing clinical effects of the newly developed therapeutic agent.
This lecture was recorded at the Asian Interchange on Diabetes meeting, held in Bangkok on July 30-31, 2016.
Video navigation menu
- Why do we need ongoing clinical innovation for the management of T2DM? 0:21
- The drug discovery and development process is a long and challenging trajectory 3:43
- Discovery of the SGLT2 transporter as a therapeutic target and finding an inhibitor 6:50
- Testing the identified compound and developing a drug 13:34
- Results of the phase I, II and III trials evaluating a SGLT2 inhibitor 16:35
- Meeting unmet needs in diabetes care: is that enough? 20:07